Name | Type | Posted | Actions |
|---|---|---|---|
Salient Characteristics Qiagen LIAISON QuantiFERON TB Gold Plus and Control.pdf | Sep 16, 2025 |
Reagents for detection of Mycobacterium Tuberculosis: Liaison QuantiFERON TB Gold Plus and LIAISON Control QuantiFERON TB Gold Plus
Contact and place of performance
Brittany Chartier
Tacoma, WA
USA
THIS NOTICE OF INTENT IS NOT A REQUEST FOR QUOTES. A DETERMINATION NOT TO COMPETE THE PROPOSED PROCUREMENT BASED UPON RESPONSES TOTHIS NOTICE IS SOLELY WITHIN THE DISCRETION OF THE GOVERNMENT. Medical Readiness Contracting Office - Pacific hereby provides notice of its intent to award a sole-source, firm fixed price contract under the authority of FAR 13.106-1(b)(1). As a result, the Government intends to award direc...
View moreThe attached salient characteristics detail the requirements of this anticipated contract action. Market Research has demonstrated that the intended awardee is the only business that is able to meet the requirements.
THIS NOTICE OF INTENT IS NOT A REQUEST FOR QUOTES; no solicitation or RFQ will be forthcoming.
Any firm that believes it can provide the stated supplies can provide supporting documents demonstrating their capabilities and certifications. Interested parties may identify their interest and capability to respond to this requirement no later than Wednesday, 17 September 2025 at 11:00 AM Pacific Time.
All documents submitted will not be returned. Responses received may be used for future acquisitions. All interested parties shall submit clear and convincing documentation demonstrating their capabilities to satisfy the requirements contained within the attached Statement of Work. The capability documentation should include general information and technical background describing in detail the prospective contractor's capabilities and experience that will demonstrate the ability to support these requirements.
Interested parties are encouraged to furnish information by email only with subject line stating - RESPONSE TO INTENT TO SOLE SOURCE FOR W81K0225QA107. Information can be sent to Brittany Chartier at [email protected]. No telephone or facsimile requests will be accepted. This procurement will be prepared in accordance with FAR Part 13, Simplified Acquisition Procedures.
Medical Readiness Contracting Office - Pacific will NOT be responsible for any costs incurred by interested parties in responding to this notice of intent. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
The Medical Readiness Contracting Office - Pacific, under the Department of the Army, has issued this combined synopsis/solicitation for the procurement of QuantiFERON TB Gold-Plus assay reagents. These reagents are used for the detection of Mycobacterium tuberculosis immune responses via enzyme immunoassay at Madigan Army Medical Center in Tacoma, Washington. The government intends to award a sole-source, firm-fixed-price indefinite delivery indefinite quantity contract to Qiagen, LLC, for a five-year ordering period. This requirement is classified under NAICS 325413, In-Vitro Diagnostic Substance Manufacturing, and PSC 6550, In Vitro Diagnostic Substances, Reagents, Test Kits and Sets. There is no set-aside assigned to this action.
The purpose of this acquisition is to maintain continuity of operations and testing capacity for latent tuberculosis infections. The QuantiFERON TB Gold-Plus assays are the only FDA-cleared interferon-gamma release assays compatible with the facility’s existing DiaSorin LIAISON XL analyzer that do not require additional instrumentation or physical workspace. According to market research, this specific product is the only one capable of meeting government requirements without necessitating new equipment and facility modifications.
While this notice serves as an intent to award a sole-source contract under FAR 13.106-1(b)(1), firms that believe they can provide the required supplies may submit documentation of their capabilities and certifications. Submissions must be sent via email to Brittany Chartier by the response deadline of September 17, 2025, at 11:00 AM Pacific Time. Supporting information is provided in the attached document titled Salient Characteristics Qiagen LIAISON QuantiFERON TB Gold Plus and Control.pdf, which was posted on September 16, 2025. This procurement follows simplified acquisition procedures under FAR Part 13, and the solicitation is identified by number W81K0225QA107.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.